Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE:R9Q) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results to date. Recce Pharmaceuticals has manufacturing facilities in Australia and clinical research partners in the USA. Recce Pharmaceuticals has...

Sepsis,superbugs,polymers,biotech,synthetic polymers,antibiotics,global health,antibiotic resistance,clinical trials,blood infections,infectious disease,fda,asx,and pharmaceuticals

Recce pharmaceuticals ltd operates in the Pharmaceutical manufacturing industry.

Recce pharmaceuticals ltd's revenue is 11m - 100m

Recce pharmaceuticals ltd has 11 - 50 employees.